A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors UCB; UCB Biosciences
- 16 Jun 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 13 Jun 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2022 This trial has been completed in Latvia (End Date: 13 April 2022) according to European Clinical Trials Database record.